Specific genetic abnormalities are seen within certain TN-BC cohorts, such as those patients with the BRCA1/2 familial breast cancer gene mutations that are responsive to PARP inhibitors, which does support the concept of targeting TN-BCs with specific cancer agents3. Here, BRCA1 is linked to breast cancer.